Trial Profile
Realizing Effectiveness Across Continents With Hydroxyurea (REACH): A Phase I/II Pilot Study Of Hydroxyurea For Children With Sickle Cell Anemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Hydroxycarbamide (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Acronyms REACH
- 01 Apr 2024 Results published in the American Journal of Hematology
- 12 Dec 2023 Results(n=635),presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology